SCHEMBL4415573

SCHEMBL4415573

O=C(O)n1ccc2c(Nc3cccc(Oc4ccccc4)c3)ncnc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIP4K2A P48426 1/20 0.47
PIK3CG P48736 1/20 0.47
SIRT2 Q8IXJ6 1/20 0.46
SIRT1 Q96EB6 1/20 0.46
CSNK2A1 P68400 3/20 0.46
CSNK2A2 P19784 2/20 0.46
CSNK2B P67870 2/20 0.46
EGFR P00533 3/20 0.46
KDR P35968 2/20 0.46
DYRK3 O43781 1/20 0.46
MAP4K4 O95819 1/20 0.46
PDGFRA P16234 1/20 0.46
LTK P29376 1/20 0.46
GRK5 P34947 1/20 0.46
MAPK8 P45983 1/20 0.46
CDK8 P49336 1/20 0.46
CDK7 P50613 1/20 0.46
IRAK1 P51617 1/20 0.46
NEK4 P51957 1/20 0.46
LIMK1 P53667 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4421383 0.82 RAB9A (0.57) PIP4K2APIK3CGEGFRCDK7DYRK1A
SCHEMBL4414264 0.82 MAPT (0.57) EGFRMAPTTP53NPC1ALDH1A1
SCHEMBL4427009 0.82 AURKA (0.58) EGFRAURKBABCG2KDM4E
SCHEMBL4415185 0.82 LMNA (0.58) PIP4K2APIK3CGEGFRMAPTSMN1; SMN2
SCHEMBL32679377 0.81 KDR (0.55) PIP4K2APIK3CGEGFRKDRTEK
SCHEMBL4412294 0.81 PIP4K2A (0.69) PIP4K2APIK3CGEGFRMAPK14ABCG2
SCHEMBL4423001 0.81 ALDH1A1 (0.54) PIP4K2APIK3CGCSNK2A1CSNK2A2CSNK2B
SCHEMBL4412666 0.81 PIP4K2A (0.48) PIP4K2APIK3CGEGFRAURKBMAPT
SCHEMBL4416495 0.80 EGFR (0.57) PIP4K2APIK3CGCSNK2A1CSNK2A2CSNK2B
SCHEMBL4416404 0.80 ABCG2 (0.57) PIP4K2APIK3CGEGFRMAPK14ABCG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1658290-A4 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2009-04-15 EP claimed
US-7338957-B2 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2008-03-04 US claimed
JP-2007504159-A 2007-03-01 JP claimed
EP-1658290-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2006-05-24 EP claimed
WO-2005039486-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2005-05-06 WO claimed
EP-1658290-A4 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2009-04-15 EP disclosed
US-20080108616-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2008-05-08 US disclosed
US-7338957-B2 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2008-03-04 US disclosed
EP-1658290-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2006-05-24 EP disclosed
WO-2005039486-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108616-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS LCK, FYN, BMX PIP4K2A 1032/4885PIK3CG 762/4885SIRT2 2279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.